Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
作者： J R Redman , F Cabanillas , W S Velasquez , P McLaughlin , F B Hagemeister
DOI: 10.1200/JCO.1992.10.5.790
关键词: Surgery 、 Fludarabine monophosphate 、 Internal medicine 、 Fludarabine Phosphate 、 Gastroenterology 、 Lymphoma 、 Chemotherapy 、 Mycosis fungoides 、 Medicine 、 Follicular phase 、 Toxicity 、 Fludarabine
摘要: PURPOSEIn a phase II trial we investigated fludarabine phosphate (FAMP) as therapy for patients with relapsed lymphoma to determine its effectiveness and toxicity in this disease.PATIENTS AND METHODSThe 67 assessable had median age of 56 years received three chemotherapy regimens before treatment FAMP. The starting dose was 25 mg/m2 administered intravenously over 30 minutes daily 5 days every 3 4 weeks.RESULTSHigh response rates were observed follicular small cleaved-cell (FSCCL) (62%), mixed small- large-cell (80%), (FLCL) (100%). Responses also occurred lymphocytic (SLL) (33%), transformed mycosis fungoides (40%), Hodgkin's disease (25%). No responses other intermediate- or high-grade lymphomas (N = 20). Overall, there five complete response, 23 partial an overall rate 37%....
sci-hub.se 参考文章(21)
S M Caryk, H G Chun, D F Hoth, B R Leyland-Jones, Central nervous system toxicity of fludarabine phosphate. Cancer treatment reports. ,vol. 70, pp. 1225- 1228 ,(1986)
MJ Keating, H Kantarjian, M Talpaz, J Redman, C Koller, B Barlogie, W Velasquez, W Plunkett, EJ Freireich, KB McCredie, Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood. ,vol. 74, pp. 19- 25 ,(1989) , 10.1182/BLOOD.V74.1.19.19
Eric H. Kraut, Louis Malspeis, Kathy M. Snider, Michael R. Grever, Earl N. Metz, Jane M. Leiby, Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity. Cancer Research. ,vol. 47, pp. 2719- 2722 ,(1987)
R P Warrell, E Berman, Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. Journal of Clinical Oncology. ,vol. 4, pp. 74- 79 ,(1986) , 10.1200/JCO.1986.4.1.74
Raymond P. Warrell, Craig J. Coonley, David J. Straus, Charles W. Young, Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion Cancer. ,vol. 51, pp. 1982- 1987 ,(1983) , 10.1002/1097-0142(19830601)51:11<1982::AID-CNCR2820511104>3.0.CO;2-L
Terrence L. Cascino, Loren D. Brown, Roscoe F. Morton, Lloyd K. Everson, Robert F. Marschke, Robert P. Dinapoli, Judith R. OʼFallon, Evaluation of fludarabine phosphate in patients with recurrent glioma. American Journal of Clinical Oncology. ,vol. 11, pp. 586- 588 ,(1988) , 10.1097/00000421-198810000-00015
EphraimS. Casper, Abraham Mittelman, David Kelson, CharlesW. Young, Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemotherapy and Pharmacology. ,vol. 15, pp. 233- 235 ,(1985) , 10.1007/BF00263892
John J. Kavanagh, Irwin H. Krakoff, Gerald P. Bodey, Phase I study of fludarabine (2-Fluoro-ara-AMP) European Journal of Cancer and Clinical Oncology. ,vol. 21, pp. 1009- 1011 ,(1985) , 10.1016/0277-5379(85)90283-4
R.W. Brockman, F.M. Schabel, J.A. Montgomery, Biologic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-d-arabinofuranosyladenine Biochemical Pharmacology. ,vol. 26, pp. 2193- 2196 ,(1977) , 10.1016/0006-2952(77)90275-1
Richard Pazdur, Michael K. Samson, Laurence H. Baker, Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas. American Journal of Clinical Oncology. ,vol. 10, pp. 341- 343 ,(1987) , 10.1097/00000421-198708000-00017